Brief: ABVC Biopharma ADHD Phase II Part 2 Clinical Study First Subject Treated
10/05/2022 14:04
May 10 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA ADHD PHASE II PART 2 CLINICAL STUDY FIRST
SUBJECT
TREATED
Source text for Eikon: ID:nGNXz5PP7
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma Says Biokey Share Distribution Rescheduled For August 21
NASDAQ RESUMED AT 09:05 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:43 PM
Brief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon